Orlando Tech News Highlights Protean's Use of AI to Fight Cancer

 
 
 

AI helps in cancer fight thanks to Orlando firm’s new partnership

Published by Orlando Tech News
Written by Marco Santana
Oct 11, 2024

An excerpt from the original article is posted below.

 


An Orlando medtech company has partnered with Canadian prostate cancer test developer Nanostics, Inc., to bring a blood-based diagnostic tool embedded with artificial intelligence to the U.S. market. The Protean BioDiagnostics partnership brought Nanotics’ ClarityDx Prostate risk score to healthcare providers last month. The tool, which uses biological data, clinical information and AI-powered learning models to generate a risk score, targets patients suspected of potentially developing aggressive prostate cancer.

Protean CEO Dr. Anthony Magliocco said the partnership made sense for the Orlando company. “We are trying to make a difference for cancer patients and general wellness,” he said in an interview with Orlando Tech News. Protean, based in UCF Business Incubation Program’s Lake Nona site, works with doctors to enhance their ability to provide quality care for patients. The company was recently named a company to watch by Grow Florida, which targets second-stage companies that indicate future growth.

Magliocco said recent trends in medical advancements have helped democratize the best treatments for even the most-severe ailments. In addition, efforts like the ClarityDx Prostate risk score helps somewhat level the playing field for private practice doctors with those based in mammoth hospital systems. “Before, you’d have to go to castles on the hill to get the best care,” he said. “Now we can bring advances to people everywhere.”

“Before, you’d have to go to castles on the hill to get the best care. Now we can bring advances to people everywhere.”
— Anthony Magliocco MD

Protean is a platform that can connect doctors, patients and support systems with test options that target specific criteria. “We are trying to gather them and make them available to people and medical systems that are underserved,” he said. “We have packaged it all up into an easy button.”

One function Protean hopes to simplify is discovering pertinent information in usually long-winded medical reports. Instead of having to read through what can sometimes be 2,000-page reports, using AI can quickly scan for usable information. “It’s like having an assistant that is tireless and finding things you missed,” Magliocco said. As stored data continues to grow, it will allow these AI-based methods of diagnosis and treatment to continually improve. The goal is to deliver better healthcare at a lower cost and higher margins for everyone, he said. 

“There is opportunity in collaboration,” he said. “We need to move past this highly competitive environment. There is massive untapped opportunity and we are just going to be squabbling over the diminishing returns.”

“We should be competing over who can get more resources out there.”

 

For further information, please contact:

Anthony Magliocco MD
CEO & President of Protean BioDiagnostics

Email: info@proteanbiodx.com
Phone: 1 (813) 817 2042

About Protean BioDiagnostics

Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support. 

We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.

About Nanostics Inc.

Nanostics Inc is a private Canadian company that develops and commercializes novel and noninvasive diagnostic tests. Its core technology, ClarityDX®, uses advanced machine learning algorithms to create a disease risk score that predicts the presence of diseases. ClarityDX is applicable to a wide range of cancers and other diseases. Nanostics’ lead product, ClarityDX Prostate®, is a test that improves the accuracy of detecting clinically significant prostate cancer. Read more at: www.nanosticsdx.com.

 
 
 
Anthony Magliocco